InvestorsHub Logo
Followers 5
Posts 224
Boards Moderated 0
Alias Born 03/19/2015

Re: juslin post# 261641

Friday, 04/03/2020 9:07:41 PM

Friday, April 03, 2020 9:07:41 PM

Post# of 425795

Not only that, she accepts Kurabayashi study as valid (even when the patients were given a lipid modifying agent) as part of the obviousness case regarding ApoB, when it clearly this is both a group of patients below 500mg/dl and taking a confounding therapy and then rejects REDUCE-IT as insufficiently linked to the case on the secondary considerations because the patients on that group were below 500mg/dl and represent a different group (even when a small group of patients in reduce-it were above 500mg/dl)

So many issues on this ruling....



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News